Celmatix Welcomes Fertility Specialists Medical Group to the Personalized Reproductive Medicine Initiative

NEW YORK, Sept. 11, 2018 /PRNewswire-PRWeb/ -- Today, Celmatix, the next-generation women's health company, announced the addition of Fertility Specialists Medical Group to the Personalized Reproductive Medicine Initiative (PReM). Comprising the premiere academic and private fertility treatment centers across the United States, PReM members are united by a common goal to leverage big data and genomics to better understand the reproductive challenges faced by millions of people around the world.

Fertility Specialists Medical Group represents one of the region's most highly regarded fertility clinics, having been named to San Diego Magazine's "Top Doctors" list for five years in a row. With two locations in San Diego and Carlsbad, California, they help patients achieve their reproductive goals by delivering comprehensive, advanced fertility care in a supportive, welcoming, and efficient environment.

"We're excited to welcome Fertility Specialists Medical Group into the PReM Initiative," said Piraye Yurttas Beim, PhD, Founder and CEO of Celmatix. "Diversity is important when building foundational datasets like the one undertaken by the PReM Initiative. The addition of FSMG expands the geographical footprint of our initiative to Southern California, but also expands the diversity of individuals and unique fertility journeys represented in our research discoveries. Dr. Morales has an impressive track record with cutting edge research in our field, and we feel privileged to be partnered with her and the talented physicians on her team."

"It's an honor to be a part of this coordinated, diverse group of organizations committed to exploring genomics in women's healthcare across the nation," said Arlene J. Morales, M.D., Medical Director and Founder, Fertility Specialists Medical Group. "Infertility is such a pervasive and physically and emotionally burdensome disease state. It's important that we advance the field to look beyond individuals' symptoms to start finding new ways to help people plan their families."

Insights from the PReM initiative have the potential to revolutionize how fertility difficulties are diagnosed, treated, and possibly prevented. For additional information on the PReM initiative, please visit http://www.celmatix.com/prem. If you or your colleagues would like to join the PReM Initiative, please contact prem(at)celmatix(dot)com.

About Celmatix Inc.

Celmatix is a next-generation women's health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them and their physicians with more personalized information. The company's research-driven products include the Fertilome® test, the world's first multigene panel test that reveals what a woman's DNA says about her reproductive health, Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience, and MyFertility Compasstm, a data-driven education tool that gives women who are currently trying to conceive insights into their fertility potential.

SOURCE Celmatix